Risk of thromboembolic events in patients with metastatic solid tumors treated with PARP inhibitors: A systematic review and meta-analysis of phase 3 randomized controlled trials

•PARP inhibitors present a favorable safety profile in the metastatic setting.•However, their potential risk of thromboembolic events (TEs) is unclear.•Our meta-analysis did not find either increased or decreased risk of TEs.•No safety alerts emerged for patients treated with PARP inhibitors.•Risk assessment for TEs should always be integrated in clinical practice.